Early Access — free while we kick the tires
EdgarHawk

Neumann Mark

EVP, Chief Commercial Officer

Officer
1 filing analyzed · 1 company · Latest 2024-08-20

Companies

Company Buys Sells Direction
Intra-Cellular Therapies, Inc. ITCI 0 2 Net selling

Activity

August 2024
medium
Sell
18,714 shares
$1,405,047
Significance 5/10

CCO Mark Neumann sold 18,714 shares of ITCI at $75.08; stock up 14.4% in 90 days but all 5 prior ITCI sales were poorly timed (positive 90d returns).

Mark Neumann, EVP and Chief Commercial Officer, sold 18,714 shares at $75.08, reducing his position by -38.7% to 29,700 shares. The company generated $161,388,000 in quarterly revenue with strong +85.5% annual growth, but remains unprofitable with a $-16,220,000 net loss in its most recent full fiscal year. The stock has appreciated 14.4% over 90 days and trades at $76.99, only 4.8% below its 52-week high. However, across his 5 prior open-market sales of ITCI, Neumann's timing has been consistently poor: all 5 prior sales showed positive 90-day returns (meaning the stock rose after each sale), with a 0% well-timed rate, contrasting with his broader cross-ticker track record of 12.50% well-timed sales. This sale follows that same pattern in a stock environment that has been climbing.

Related insiders

Create a free account

Build watchlists, get email alerts on the tickers you follow, and read the full AI analysis on every insider filing.

Sign up — free during early access